


A photograph of three people sitting on a blue sofa in a modern living room. On the left, a woman with long dark hair, wearing a white blazer and shorts, has a silver prosthetic right leg and is wearing white sneakers. In the middle, a woman with long brown hair, wearing a white sleeveless dress, has a prosthetic right leg decorated with colorful flowers and is wearing tan sandals. On the right, a man with short grey hair and glasses, wearing a light blue button-down shirt and khaki shorts, has a silver prosthetic right leg and is wearing white sneakers. They are all smiling and looking at each other. In the background, there is a white shelf with a vase of green plants and some books. In the foreground, a round wooden coffee table holds two glasses of water and a plate of fruit.

ottobock.

Ottobock SE & Co. KGaA Global MedTech Champion


September 2026

Ottobock at a glance - FY 2025



Note: 1) Company data analysis; relates to human bionics market comprising relevant B2B markets (incl. Prosthetics, Neuro-Orthotics, Digital O&P solutions, Occupational Exoskeletons) and B2C Patient Care market, based on estimated revenue for 2025; 2) Core business comprises B2B and B2C business excluding non-core business activities. Non-core comprises subsidiaries or business areas which have been divested or closed or for which a divestment or closure within the next 18 months was approved by the board.; 3) Total core revenue defined as total revenue generated by core business ; 4) Organic core revenue growth 24A-25A defined as average YoY organic core revenue growth from 2024 to 2025; 5) Underlying core EBITDA defined as underlying EBITDA generated by core business; 6) Underlying core EBITDA margin defined as underlying core EBITDA / total core revenue; 7) As per 31 December 2025; 8) Countries where Ottobock has a local presence, where products are actively marketed by or on behalf of Ottobock and/or where patients have their main abode; 9) Refers to the total patient base for financial year 2025 incl. new patients and patients re-fitting; 10) As per 31 December 2025 plus new Patient Care clinics added in 2026 (e.g. Blatchford, Norway)


Over a century of continuous innovation leadership




Note: 1) Acquisition of Exoneural Network (developer of Exopulse Suit) in January 2021; Exopulse Suit was already developed in 2017/2018

Integrated platform with a comprehensive offering

Medical conditions served



Integrated platform with a comprehensive offering



Note: 1) Company data analysis; referring to # amputee prevalence in 2024 (major amputations), including Congenital and Other; 2) Company data analysis; referring to prevalence with a relevant mobility impairment in 2024 (capped at 100% of prevalence in case of multiple impairments); 3) Revenue share based on 2025A total core revenue; 4) Including PEM (planning, equipment and materials); 5) Focus on occupational applications for the able-bodied; 6) B2B business comprises healthcare product and corresponding service sales through healthcare providers to retail customers; 7) B2C business comprises patient treatment by own Patient Care clinics including product sales and fitting services; 8) Includes Arthritis, Parkinson's disease, Traumatic Brain Injury, and Tremor

Comprehensive portfolio of bespoke solutions

Prosthetics



Neuro-Orthotics



Innovation - The next major milestones

Vision

Human Bionic Reconstruction

Prosthetics

Neuro-Orthotics

Present

**Expansion of upper and lower limb
mechatronic systems**

**Expansion of lower limb
mechatronic portfolio**


**Near
Future**

**Next gen active prosthetics
enabled by man-machine interfaces**

Introduction of upper limb systems



Ottobock – Global MedTech champion

**1**

Global market leader in Human Bionics¹⁾

#1 in Prosthetics, #1 in Neuro-Orthotics, #1 in Exoskeletons, #1 in Digital O&P

2

Highly attractive and resilient markets

with strong growth momentum

3

Innovation champion with strong pipeline creating new markets and socioeconomic benefit

4

Scalable business model

rolling out innovative tech-driven products through a global sales network and own Patient Care clinics with direct patient access

5

Strong financial profile

with track record of double-digit growth and margin expansion

Note: 1) Company data analysis; relates to human bionics market comprising relevant B2B markets (incl. Prosthetics, Neuro-Orthotics, Digital O&P solutions, Occupational Exoskeletons) and B2C Patient Care market, based on estimated revenue for 2024

Ottobock Investor Presentation September 2026 | Copyright © 2026 Ottobock


1 Global market leader in Human Bionics

Key market drivers


- Ageing society accompanied by growing chronic health conditions
- Scale-up of tech-driven innovations
- Steady expansion of reimbursement access
- Increasing patient access to O&P solutions
- Spike events⁴⁾

Ottobock's addressable market sizes, market positions and expected market growth

Products & Components (B2B)¹⁾



Patient Care (B2C)



Source: Company data analysis

Note: 1) B2B market including Prosthetics, Neuro-Orthotics, Digital O&P excluding PEM (planning, equipment and materials), and Exoskeletons; 2) Addressable market size based on estimated revenue for 2024. Market position measured by estimated 2024 market size and estimated 2024 revenue; 3) Expected CAGR over 2024-2030E; 4) Spike events are defined as events that are typically sudden and unforeseen, causing shifts in markets, which include, among others, the Russia / Ukraine war, the Israel / Gaza conflict and the 2023 earthquake in Türkiye


Ottobock Investor Presentation September 2026 | Copyright © 2026 Ottobock

8


② Highly attractive and resilient markets

Addressable B2B market (in bn. €)

CAGR
2024-30




Addressable B2C market (in bn. €)



Source: Company data analysis

Note: 1) Includes mechatronic and mechanic knee and foot as well as Upper Limb prosthetics and liner / other socket tech; 2) Includes Basic Orthotics, Functional Electrical Stimulation (FES), Mechatronic Orthotics, and Neuromodulators; 3) Excluding PEM (planning, equipment and materials); 4) Focus on occupational applications for the able-bodied; 5) Spike events are defined as events that are typically sudden and unforeseen, causing shifts in markets, which include, among others, the Russia / Ukraine war, the Israel / Gaza conflict and the 2023 earthquake in Türkiye

③ Evidence-based benefits are driving reimbursement



Flag Reimbursement coverage through public health insurance obtained (may require special application/motivation)


Source: Company data analysis

Note: 1) Reimbursement access established based on predecessor version in 2014 (Germany) and 2016 (Switzerland); 2) Select reimbursement through private, military foundation, occupational insurance, government schemes; 3) Acquisition of Exoneural Network (developer of Exopulse Suit) in January 2021

Ottobock Investor Presentation September 2026 | Copyright © 2026 Ottobock

10


4 Scalable business model across B2B and B2C



Note: 1) General and Administrative shared services refer to the centralization of support functions (incl. Finance, HR, IT, Procurement)

4 Patient population growth through re-fitting cycles


>5 re-fitting cycles with >€150k LTV¹⁾



Chronic conditions with multiple re-fitting cycles

Up- and cross-selling opportunities

Case study: Revenue development of MPK products in DACH




Note: 1) LTV = Customer lifetime value; Illustrative example for an average Traumatic Limb Loss patient in Germany. Calculation assuming an average life expectancy of 80 years, an initial fitting at the age of 40, an average replacement cycle for knee joints of six years, an average replacement cycle for the foot of three years, as well as Ottobock's average DACH sales prices of 2024 across knee joints (incl. accessories and warranty packages), and foot

Ottobock Investor Presentation September 2026 | Copyright © 2026 Ottobock

4 Digitalization and industrialization of our global Patient Care network

Ottobock global Patient Care network¹⁾

More than **3x network expansion** since 2016



Increased efficiency through digitalization

~**40%** time saving²⁾



Administration



3D scan



Digital fabrication




Fitting

Note: 1) As per June 2026

Ottobock Investor Presentation September 2026 | Copyright © 2026 Ottobock

5 Double-digit sales growth and over-proportionate profit and free cash flow increase




● Org. core cc growth rate ● Underlying core EBITDA margin

Ottobock Investor Presentation September 2026 | Copyright © 2026 Ottobock


⑤ Outperforming markets in all regions

EMEA (in m. €)




- New product launches
- Reimbursement expansion
- Spike events

Americas (in m. €)




- New product launches
- Reimbursement expansion

APAC (in m. €)



- Strong growth in Australia and Japan
- Growth acceleration in emerging markets

⑤ Successful interplay of B2B and B2C




Patient Care (B2C)

- Strong catch-up after weaker start into the year
- US business with double-digit organic growth
- Further contribution from acquisitions in EMEA and APAC

Products & Components (B2B)

- **Prosthetics:** Market penetration of innovative products for lower and upper limb; spike event impact
- **Neuro-Orthotics:** Ramp-up of high-end products supported by reimbursement expansions
- **Digital O&P:** Continuous growth and investment in portfolio expansion with Romedis acquisition

5 Strong profitability in all regions – Americas picked up as planned



Gross Profit

- Positive product mix with strong B2B sales
- Scaling effects and benefits from lower cost manufacturing plants and procurement initiatives

Operating costs

- Positive scaling effects
- Global Value & Efficiency Program (GVEM) incl. further ramp-up of shared service center in Bulgaria

Segments

- Positive underlying core EBITDA margin development across all segments
- Americas with margin increase due to strong sales growth in B2B and B2C business

Business and Strategy Update



What are the key themes for 2026

Innovation-driven demand

- **OTWorld 2026 launches** and **ramp-up from H2/26**
- **Continued X4, Kenevo** (US K2 segment), **new upper limb platform roll-out**, and **C-Brace France reimbursement**
- **Increasing O&P demand** across Ukraine / Russia, **slowly increasing demand** in Israel/ Gaza and **potential upside** from Iran conflict

H1/26

H2/26



Scalability

- **Further margin expansion** through overproportionate growth of high-end O&P portfolio
- **Proven delivery** of operational efficiency measures

H1/26

H2/26

Continuous

Seasonality

- Structural seasonality pattern **expected to persist in 2026**
- **Non-systematic delays related to geopolitics** in the first months of 2026 but **full catch-up expected**

H1/26

H2/26



M&A

- **Execution on attractive M&A pipeline** on technology and product portfolio expansion and Patient Care related 'buy-and-build'
- **Disposal of non-core activity**

H1/26

H2/26

Continuous



Select Innovations for OTWorld



Iconiq Liner

- Essential part of every prosthetic fitting, exchanged every 6 months
- Next generation liner family
- Better fit, skin health, and comfort



Michelangelo

- Strengthens our upper limb portfolio
- One of the most advanced bionic hands in the world
- Part of our new upper limb platform, one control system across devices



C-Brace Interim


- Pioneering microprocessor controlled leg orthosis
- Fitted in the hospital within hours
- Enables early rehabilitation and significantly enlarges the patient pool



Revoniq

- New SSCO joint, complements C-Brace
- For lower activity levels and less impaired patients
- App free, adjustable directly by the clinician

Launch of new innovations driving non-linear growth



What to expect in 2026

Significant number of **next gen products** presented at OTWorld in May 2026

Full suite of innovations across entire product range to further **evolve the portfolio**

High demand for next gen products will **drive growth** with full year impact to be realized by 2027

New launches in exoskeletons include **AI-based ergonomic tool** and **Powered Back Volton Exoskeleton**


Delivering on our scalability targets

Scalability measures

-  Innovation-driven growth
-  Production relocation towards Bulgaria (LCM)
-  Shared service center Bulgaria
-  Procurement initiatives
-  Industrialization of patient care network


 High impact  Low impact

Successful margin development



Recurring seasonality pattern with a clear upward trend on a full-year basis

Core revenue development



Commentary

Structural seasonality pattern alongside special effects

H2 weighting reflects reimbursement approval patterns, with payer decisions typically accelerating towards year-end

Prior-year **product launches** increasingly **contribute on a full run-rate basis by Q4**

Smoothing of capacity utilization with strong **positive impact towards end of year profitability**

Active M&A approach & ongoing non-core portfolio measures

Non-core portfolio measures

- ✓ **A4 Access**
Divested (January 2024)
- ✓ **Cascade Orthopedic Supply**
Divested (September 2024)
- ✓ **Active Life Health**
Closed down (December 2024)
- ✓ **Otto Bock Human Mobility**
Sale agreement signed (June 2026),
closing expected for end of H2 2026
- **Otto Bock Orthopedic Services**
Designated for exit

Acquisitions / investments



Note 1): Expansion of former investments in 2025

Financial Update H1 2026 and Outlook




Delivering strategic priorities and operational target

- 1** Strategically & operationally on track with strong Q2 performance
- 2** Organic core revenue growth of +6.7% in H1 (Q2 2026: +8.0%), driven by EMEA with a continued growing patient base
- 3** Underlying core EBITDA margin improved to 25.3% in H1 (Q2 2026: 27.9%)
- 4** M&A¹: 1) acquired Neuro-Orthotics/FES tech platform; 2) acquired leading patient care network in Norway; 3) signed Human Mobility divestment
- 5** 2026 guidance narrowed: organic core revenue growth 6.0–8.0% (previously: 5.0–8.0%), u. core EBITDA margin of > 27.0% (previously: > 26.5%)

¹ Neuro-Orthotics/FES tech platform signed in July 2026, not listed: equity investment in Blue Arbor Technologies, Inc.




Strong organic core growth of +6.7% in H1, led by B2B in EMEA




Announced innovation launches from OTWorld are on track: new product generations in prosthetics and neuro orthotics with michelangelo, iconiq liner and C-Brace Interim strengthen Ottobock's innovation leadership

Strong organic core growth of +6.7%, margin expansion by +2.2%p reaching 25.3% in H1


Core revenue (in m. €)



Underlying core EBITDA (in m. €)



Free cash flow (in m. €)




- Q2 delivered as expected with org. core growth of +8.0% after solid start into the year (Q1 org. growth: +5.1%)

- Margin increase of +2.2%p to 25.3% in H1 driven by scaling and efficiency gains
- Q2 with strong margin of 27.9%

- H1 free cash flow impacted by timing effects and one-offs of tax payments

B2B with high single digit organic growth of +8.7% in H1

Core revenue (in m. €)



Commentary

Patient care (B2C)


- **Continued positive org. core growth** momentum
- Acquisition of **Blatchford's patient care business in Norway**

Products & components (B2B)

- **Accelerated org. core growth of +11.7% in Q2** after softer start into the year (Q1 org. growth: +5.5%)
- Continued positive momentum in **prosthetics and neuro-orthotics** driven by Genium X4, Kenevo and C-Brace


EMEA key growth driver in Q2, Americas and APAC with strong comps

Core revenue EMEA (in m. €)




- Double-digit organic core growth in B2B with strong Q2 momentum
- B2C growth in line with market growth

Core revenue Americas (in m. €)



- US with strong comparison period; positive trend vs. Q1 on B2B side
- Canada and LATAM with dilutive effect


Core revenue APAC (in m. €)



- Timing effects compared to prior year; positive H2 outlook

Underlying core EBITDA increase by +18% in H1; significant margin uplift

Underlying core EBITDA (in m. €)



Commentary

Group


- Favorable product mix effects through strong growth in B2B business
- Disciplined cost management especially in administrative and distribution functions
- Scaling effects and efficiency gains

Segments

- Positive underlying core EBITDA margin development across all segments

Increase in underlying net income by +24% in H1

Underlying net income (in m. €)




Commentary

- **Depreciation** (excluding impairments) rose in line with business development
- **Interest** result below prior year driven by lower average net debt and lower bank interest rates
- **Improved tax rate** compared to H1 2025, but higher absolute income tax expenses as a result of improved profitability

Lower free cash flow impacted by timing and one-off effects of income tax payments

Free cash flow (in m. €)



Commentary

Free cash flow


- EBITDA significantly above prior year
- Timing effects related to income tax payments
 - H1 2025 impacted by delayed income tax payments of € ~20 m.
 - One-offs effects of € ~10 m. including tax refunds expected for 2027

Net debt and leverage slightly increased due to Blatchford Norway acquisition

Key financial indicator

	Q4 2025	H1 2026
Net debt	960.7	1,124.7
LTM u. EBITDA	420.7	453.2
Leverage	2.3x	2.5x

Net debt (in m. €) and leverage



2026 outlook narrowed, mid-term guidance on track

	Previous guidance 2026	Narrowed guidance 2026	Mid-term guidance 2029
Organic core revenue growth	5.0–8.0%	6.0–8.0%	7.0–9.0% p.a.
Underlying core EBITDA margin	> 26.5%	> 27.0%	29.0–30.0%
Net capex and cap. R&D	€ 105 m. – 115 m.	€ 105 m. – 115 m.	
Cash-effective tax rate	~ 25%	~ 35%	
Leverage	< 2.0x	< 2.0x	

Key Themes

- Innovation-driven growth: New product launches
- Increasing demand in Ukraine-Russia with continued growing patient base
- Scalability: Operational efficiency driving profitability



Appendix

Ambitious leadership team committed to long-term success

Executive Directors



Oliver Jakobi
(CEO/CSO)



Dr. Arne Kreitz
(CFO)



Arne Jörn
(COO/CTO)



Martin Böhm
(CXO)

Execution-driven management team with
Ottobock DNA and **strong track record**

Clear strategic roadmap to drive growth
and **margin expansion**

Non-Executive Directors



**Prof. Hans Georg
Näder**
Chairman &
majority owner



**Dr. Katarzyna
Mazur-Hofsäb**
Former member of the
Management Board of
Fresenius Medical Care



**Dr. Joachim
Kreuzburg**
Former CEO
Sartorius



**Eva
van Pelt**
Former Co-CEO
Eppendorf



**Prof. Dr. Michael
Kaschke**
Former CEO
Zeiss

Supported by **highly experienced
industry experts**

Full support and long-term commitment
of the Näder family



Years at Ottobock

Key figures

million €	Q2		H1	
	2025	2026	2025	2026
Revenue	417.7	458.1	800.6	854.1
Revenue growth	5.2%	9.7%	5.0%	6.7%
Core revenue	397.7	440.1	760.2	818.5
Organic core revenue growth	10.9%	8.0%	10.9%	6.7%
Gross profit	228.7	242.0	423.8	448.5
Gross margin	54.8%	52.8%	52.9%	52.5%
Underlying EBITDA	104.2	127.1	180.3	213.2
Underlying EBITDA margin	24.9%	27.8%	22.5%	25.0%
Underlying core EBITDA	99.8	122.7	175.2	207.0
Underlying core EBITDA margin	25.1%	27.9%	23.1%	25.3%
EBITDA	93.2	124.9	163.6	208.0
EBITDA margin	22.3%	27.3%	20.4%	24.4%
Net income	11.9	48.5	28.0	67.3
Net income margin	2.9%	10.6%	3.5%	7.9%
Underlying net income	48.7	62.5	68.7	85.1
Underlying net income margin	11.7%	13.6%	8.6%	10.0%

Key figures by segment and product category

million €	Q2		H1	
	2025	2026	2025	2026
EMEA	282.5	327.5	544.0	610.2
Americas	87.8	86.8	164.2	155.8
APAC	27.4	25.8	52.0	52.5
Core revenue	397.7	440.1	760.2	818.5
Products & components (B2B)	221.2	248.0	428.5	461.6
Patient care (B2C)	176.4	192.0	331.7	356.9
Core revenue	397.7	440.1	760.2	818.5
EMEA	71.5	93.2	127.7	158.3
Americas	21.5	23.2	35.5	36.1
APAC	6.8	6.3	12.1	12.5
Underlying core EBITDA	99.8	122.7	175.2	207.0

Profit & loss statement

million €	Q2		H1	
	2025	2026	2025	2026
Revenue	417.7	458.1	800.6	854.1
Cost of sales	-189.0	-216.1	-376.8	-405.6
Gross profit	228.7	242.0	423.8	448.5
Selling expenses	-85.1	-83.1	-168.9	-172.3
Research and development expenses	-18.7	-20.7	-37.4	-40.5
Administrative expenses	-62.9	-54.4	-117.0	-106.5
Other operating income and expenses	-33.4	0.7	-34.1	2.6
Operating profit (EBIT)	28.7	84.5	66.2	131.8
Financial result	-10.4	-15.5	-20.4	-32.6
Profit before tax (EBT)	18.3	69.0	45.8	99.2
Income taxes	-6.4	-20.5	-17.9	-31.9
Profit for the period	11.9	48.5	28.0	67.3
of which attributable to shareholders of Ottobock SE & Co. KGaA	12.0	48.8	29.4	67.8
of which attributable to non-controlling interests	-0.1	-0.3	-1.5	-0.6

Balance sheet

Assets

million €	31 Dec 2025	30 Jun 2026
Property, plant and equipment	236.9	236.4
Goodwill	509.8	575.0
Intangible assets	343.4	393.7
Right-of-use assets	195.4	209.4
Equity-accounted investees	8.1	14.3
Other financial assets	46.0	39.0
Other assets	3.7	2.9
Deferred tax assets	73.9	75.7
Non-current assets	1,417.3	1,546.5
Inventories	215.6	239.6
Trade and other receivables	211.0	244.4
Other financial assets	20.7	9.8
Cash and cash equivalents	90.4	93.6
Other assets	54.4	68.0
Income tax assets	22.2	33.8
Assets held for sale	18.1	20.8
Current assets	632.3	710.0
Total assets	2,049.6	2,256.6

Balance sheet

Liabilities

million €	31 Dec 2025	30 Jun 2026
Subscribed capital	64.0	64.0
Capital reserve	153.8	153.8
Retained earnings	223.4	228.9
Other components of equity	-51.1	-51.0
Equity attributable to shareholders of Ottobock SE & Co. KGaA	390.1	395.7
Non-controlling interests	7.4	6.5
Total equity	397.5	402.2
Liabilities to credit institutions	651.6	912.6
Lease liabilities	159.7	172.3
Other financial liabilities	13.4	12.0
Other provisions	10.6	11.7
Contract liabilities	42.2	44.5
Employee benefit liabilities	24.3	23.5
Other liabilities	8.4	12.1
Deferred tax liabilities	74.4	86.1
Non-current liabilities	984.7	1,274.7

Balance sheet

Liabilities

million €	31 Dec 2025	30 Jun 2026
Liabilities to credit institutions	198.0	90.0
Lease liabilities	41.8	43.4
Trade and other payables	99.6	111.5
Contract liabilities	32.2	37.0
Other financial liabilities	31.6	32.3
Payables from reverse factoring	66.6	72.0
Income tax payable	37.1	34.4
Other provisions	33.3	33.6
Employee benefit liabilities	90.8	80.6
Other liabilities	24.8	32.7
Liabilities directly associated with the assets held for sale	11.8	12.0
Current liabilities	667.5	579.6
Total equity and liabilities	2,049.6	2,256.6

Cash flow statement

million €	Q2		H1	
	2025	2026	2025	2026
Profit before tax (EBT)	18.3	69.0	45.8	99.2
Financial result	10.4	15.5	20.4	32.6
Depreciation, amortization and impairment	64.5	40.4	97.4	76.2
Gain/loss from disposals of non-current assets	-0.3	-0.3	-0.5	-0.3
Changes in liabilities from the MPP	4.0	0.0	5.4	0.0
Other non-cash expenses and income	-1.4	4.9	-4.8	5.3
Change in operating assets and liabilities				
Inventories	-7.1	-4.6	-23.0	-21.9
Trade and other receivables	-4.8	-20.0	4.5	-19.8
Other assets	1.0	1.1	-8.1	-13.1
Other provisions	-1.6	-0.8	1.0	1.2
Trade and other payables	-6.8	-3.8	-19.7	9.4
Other liabilities	9.7	-15.7	20.1	-5.6
Income tax paid	-0.4	-32.3	-3.7	-45.3
Cash flow from operating activities	85.6	53.4	134.8	118.0
Additions to property, plant and equipment and int. assets	-27.0	-23.8	-47.2	-47.3
Disposals of property, plant and equipment and int. assets	3.1	0.6	5.5	1.0
Free cash flow	61.7	30.2	93.2	71.8

Cash flow statement

million €	Q2		H1	
	2025	2026	2025	2026
Acquisition of subsidiaries	-8.7	-1 06.3	-17.5	-111.5
Cash flow from investing activities	-43.3	-136.9	-69.8	-165.2
Proceeds from bank loans	21.4	190.9	7.1	270.0
Repayment of bank loans	0.0	-22.6	0.0	-122.6
Repayment of lease liabilities	-10.7	-11.4	-21.6	-22.3
Dividends paid	-15.0	-62.1	-15.0	-62.1
Interest paid	-12.7	-7.6	-28.1	-22.4
Contributions by shareholders	0.0	0.0	0.0	8.4
Change in other financing activities	-10.5	6.0	5.2	2.3
Cash flow from financing activities	-27.5	92.7	-52.5	50.9
Change in cash and cash equivalents	14.9	9.2	12.5	3.6
Cash and cash equivalents at the beginning of the period	76.2	85.3	76.7	90.9
Effect of foreign exchange rate changes on cash & cash equivalents	-2.6	-0.8	-0.8	-0.3
Reclassifications relating to assets held for sale	-0.6	-0.1	-0.6	-0.6
Cash and cash equivalents at the end of the period	87.8	93.6	87.8	93.6

Investor relations contact



Jens-Philipp Briemle

Vice President Investor Relations

Mobile: +49 151 5916 7524

E-Mail: investors@ottobock.de

Financial reporting

12 November 2026

Quarterly Statement January-September 2026

Roadshows and conferences

September 2026 – European Roadshows

Zurich, Frankfurt and Paris

9 September 2026

Goldman Sachs European Medtech and Healthcare Services Conference, London

22 September 2026

Bank of America Global Healthcare Conference, London

23 September 2026

Berenberg German Corporate Conference, Munich

24 September 2026

Baader Investment Conference, Munich

16 November 2026

BNP Paribas MidCap CEO Conference, Paris

23 November 2026

Deutsches Eigenkapitalforum, Frankfurt

3 December 2026

Berenberg European Conference, London

Link:

<https://investors.ottobock.com/en/events>

Disclaimer

This presentation includes statements concerning the future performance of Ottobock. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Ottobock undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release.

For this presentation, all monetary values and financial data are denominated in millions of Euros (million €). Unless explicitly specified otherwise, every numerical reference to currency should be interpreted as the stated amount multiplied by one million Euros. This convention is applied consistently throughout the presentation to ensure clarity and uniformity in financial reporting.

The key figures in the report are rounded in accordance with standard commercial practice. In individual cases, rounding may result in values in this report not adding up precisely to the amount stated, with corresponding percentages not tallying.